OBJECTIVE: To provide an up-to-date summary of current literature on the management of adverse effects of androgen deprivation therapy (ADT).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
SUBJECTS: All men suffering from prostate cancer who are treated with androgen deprivation therapy.
METHODS: All relevant medical literature from 2005 to 2014 and older relevant papers were reviewed to formulate this article. Recent health advisory statements from the Australian government, societies and advocacy groups have been incorporated to the document.
RESULTS: There are numerous adverse effects of ADT that require pro-active prevention and treatment. Ranging from cardiovascular disease, diabetes and osteoporosis to depression, cognitive decline and sexual dysfunction, the range of adverse effects is wide. Baseline assessment, monitoring, prevention and consultation from a multidisciplinary team are important in minimizing the harm from ADT.
CONCLUSIONS: This review provides series of practical recommendations to assist with managing adverse effects of ADT.
Rhee H, Gunter JH, Heathcote P, Ho K, Stricker P, Corcoran NM, Nelson CC. Are you the author?
Department of Urology, Princess Alexandra Hospital, Brisbane, Australia; Australian Prostate Cancer Research Centre, Queensland Branch, Brisbane, Australia.
Reference: BJU Int. 2014 Oct 18. Epub ahead of print.